Clinical Trial Update: Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma [Phase 2]

View source ↗

Summary

The Phase 2 open-label study of the radiopharmaceutical I-131-CLR1404 in recurrent glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• I-131-CLR1404 (Iodine-131 labeled CLR1404)

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Glioma | Phase 2 | Status: WITHDRAWN